Daily Sepsis Research Analysis
Across three notable studies, investigators advanced sepsis science from bench to bedside: an oral manganese-doped carbon dot nanotherapy mitigated sepsis-associated lung injury via the gut-lung axis; a pediatric cohort comparison suggested additive benefits of a selective cytopheretic device with CRRT in septic AKI/MODS; and integrative transcriptomics with Mendelian randomization identified PRMT-related genes linked to immune dysregulation in sepsis.
Summary
Across three notable studies, investigators advanced sepsis science from bench to bedside: an oral manganese-doped carbon dot nanotherapy mitigated sepsis-associated lung injury via the gut-lung axis; a pediatric cohort comparison suggested additive benefits of a selective cytopheretic device with CRRT in septic AKI/MODS; and integrative transcriptomics with Mendelian randomization identified PRMT-related genes linked to immune dysregulation in sepsis.
Research Themes
- Gut–lung axis and redox-active nanotherapies in sepsis
- Extracorporeal immunomodulation for pediatric septic AKI/MODS
- Epigenetic regulation and transcriptomic signatures (PRMT) in sepsis
Selected Articles
1. Oral Multi-Enzymatic Manganese-Carbon Dots Alleviate Sepsis-Associated Lung Injury via the Gut-Lung Axis.
In murine sepsis models, oral Mn-doped carbon dots displayed multi-enzymatic (SOD, CAT, POD, GPx-like) antioxidant activity, reshaped the gut–lung axis, and improved systemic and lung injury indices. Single-cell and transcriptomic data indicated enhanced macrophage efferocytosis and anti-inflammatory states, with integrated meta-omics showing Mn-CD–associated microbiome/metabolite shifts.
Impact: Introduces a mechanistically grounded, oral nanotherapeutic that targets the gut–lung axis and macrophage efferocytosis in sepsis-associated lung injury, supported by multi-omics. This platform suggests a new translational path for redox and microbiome-based interventions.
Clinical Implications: While preclinical, Mn-CDs highlight an adjuvant strategy to modulate the gut–lung axis and oxidative stress in sepsis. If safety and efficacy translate, they could complement anti-infectives to reduce lung injury.
Key Findings
- Mn-CDs exhibited multi-enzyme mimetic activities (SOD-, CAT-, POD-, GPx-like) and potent ROS scavenging.
- In murine sepsis, Mn-CDs improved systemic indices and mitigated lung injury while promoting anti-inflammatory macrophage states with enhanced efferocytosis.
- Single-cell and transcriptomic profiling revealed sepsis-associated alveolar apoptosis and impaired efferocytosis, which were countered by Mn-CDs; integrated meta-omics showed microbiome/metabolite shifts.
Methodological Strengths
- Multi-omics integration (single-cell, bulk transcriptomics, metagenomics, metabolomics) linking mechanism to phenotype
- Oral delivery nanoplatform with demonstrated biochemical multi-enzyme mimetic activity
Limitations
- Preclinical murine models limit generalizability to humans
- Long-term safety, biodistribution, and dose-response data in large animals/humans are lacking
Future Directions: Define pharmacokinetics, safety and dosing in large animals; validate efficacy in polymicrobial sepsis and co-morbidity models; plan early-phase clinical trials targeting sepsis-associated lung injury.
Sepsis-induced pulmonary injury represents a life-threatening global health challenge due to poorly defined pathological mechanisms. The gut-lung axis has been proven to be widely involved in sepsis-induced lung injury, yet effective interventions targeting gut microbiota homeostasis remain unknown. Single-cell sequencing revealed increased alveolar apoptosis and impaired macrophage efferocytosis during sepsis pathogenesis. Thus, we designed oral manganese-doped carbon dots (Mn-CDs) to alleviate septic lung injury by remodeling gut microbiota homeostasis and targeting the gut-lung axis. Biochemical characterization demonstrated Mn-CDs possess multienzyme mimetic activities (SOD-, CAT-, POD-, GPx-like) and potent ROS scavenging capacity. In murine sepsis models, Mn-CDs significantly improved systemic indices and were associated with macrophage anti-inflammatory states with enhanced efferocytosis, as evidenced by transcriptomic profiling. Integrated metagenomic/metabolomic analyses identified Mn-CDs-mediated enrichment of
2. Use of the Selective Cytopheretic Device with Continuous Renal Replacement Therapy in Children: A Comparison of Contemporary Cohorts.
In children with AKI and MODS on CRRT, adding SCD was associated with shorter CRRT duration and ICU length of stay. Survival benefits were suggested overall (Bayesian probability >99%) and were significant in septic patients (100% vs 69% survival).
Impact: Provides clinically actionable comparative data and Bayesian evidence supporting extracorporeal immunomodulation during CRRT in pediatric septic AKI/MODS, motivating confirmatory trials.
Clinical Implications: Consider SCD as an adjunct to CRRT in carefully selected pediatric septic AKI/MODS patients within trials or centers with expertise, while awaiting larger randomized evidence.
Key Findings
- SCD cohort (n=18) vs CRRT cohort (n=178): shorter CRRT duration (median 6 vs 10 days, p=0.013).
- Shorter ICU length of stay among survivors with SCD (median 16 vs 27 days, p=0.012).
- Survival: 94% vs 74% (p=0.079) overall with Bayesian probability >99% of improved survival; in septic sub-analysis, survival 100% vs 69% (p=0.032), with reduced CRRT duration and ICU LOS.
Methodological Strengths
- Multicenter comparative design leveraging prospective interventional SCD datasets and a large registry
- Use of Bayesian analysis to quantify probability of benefit
Limitations
- Non-randomized comparison with small SCD sample (n=18) and potential confounding
- Heterogeneity across centers and studies; survival signal needs confirmation
Future Directions: Conduct adequately powered, randomized, multicenter trials to confirm survival benefits, define optimal timing/dose, and identify subgroups (e.g., septic shock) most likely to benefit.
INTRODUCTION: The selective cytopheretic device (SCD) is a cell-directed extracorporeal therapy approved for use in children with acute kidney injury (AKI) receiving continuous renal replacement therapy (CRRT) with sepsis/sepsis-like conditions. We compared outcomes for children treated with SCD to a contemporary cohort of children treated with CRRT alone. METHODS: Secondary analysis and comparison of patients ≤22 years old and ≥10 kg from a multicenter registry of patients receiving CRRT for AKI and/or fluid overload (WE-ROCK; 2015-2021) to patients from two multicenter, prospective, interventional studies of children with AKI and multiple organ dysfunction (MODS) receiving SCD (SCD-PED-01/SCD-PED-02; 2016-2022). RESULTS: Eighteen patients in the SCD cohort were compared to 178 in the CRRT cohort. There were no differences between cohorts at CRRT ± SCD initiation. SCD patients had shorter CRRT duration (6 [3, 11] vs. 10 [5, 18] days, p = 0.013) and shorter ICU length of stay (LOS) in survivors (16 [11, 25] vs. 27 [16, 46] days, p = 0.012). Survival to ICU discharge or day 60 was 94% in the SCD cohort vs. 74% in the CRRT cohort (p = 0.079). A Bayesian analysis demonstrated a >99% probability of improved survival with SCD. A sub-analysis in septic patients demonstrated greater survival (100% vs. 69%, p = 0.032), shorter CRRT duration (5 [3, 7] vs. 11 [6, 17] days, p = 0.006) and reduced ICU LOS in survivors (21 [10, 25] vs. 27 [16, 45] days, p = 0.027) in SCD-treated patients. CONCLUSIONS: The addition of SCD therapy in children with AKI and MODS receiving CRRT may be beneficial, though larger prospective studies are needed.
3. Identification and validation of key genes related to arginine methylation modification in sepsis using transcriptome combined with Mendelian randomization analysis.
Integrating differential expression, WGCNA, Mendelian randomization, and machine learning across two sepsis cohorts, the authors identified ELAC2, PBX2, MCTP2, and EMB as PRMT-related key genes with AUC >0.7. GSEA and immune infiltration analyses linked these genes to translational/metabolic pathways and neutrophil, NK, and CD8+ T-cell signatures.
Impact: Provides a rigorous, multi-method pipeline linking arginine methylation to immune cell perturbations in sepsis and yields cross-dataset gene signatures that can guide biomarker and mechanistic studies.
Clinical Implications: Key PRMT-related genes could inform risk stratification and therapeutic targeting pending experimental and clinical validation.
Key Findings
- Intersection of 4,246 DEGs with 1,884 WGCNA module genes yielded 969 PRMT-related candidates.
- MR and machine learning identified ELAC2, PBX2, MCTP2, and EMB as key genes with AUC >0.7 in GSE65682 and GSE134347.
- GSEA implicated cytoplasmic translation, ncRNA metabolism, and metabolic processes; immune infiltration linked PBX2 to neutrophils and ELAC2/MCTP2/EMB to activated NK and CD8+ T cells.
Methodological Strengths
- Integration of WGCNA, Mendelian randomization, and machine learning across independent datasets
- Cross-cohort ROC validation (AUC >0.7) with pathway and immune infiltration analyses
Limitations
- Computational analysis without experimental validation limits causal inference
- Clinical utility as biomarkers remains untested in prospective cohorts
Future Directions: Experimentally validate PRMT-related genes in patient samples and model systems; test mechanistic links to lymphopenia and evaluate prognostic/theranostic performance in prospective studies.
BACKGROUND: Patients with sepsis often exhibit a decrease in lymphatic numbers, which can be facilitated by protein arginine methyltransferase (PRMT). However, it is unclear how PRMT contributes to lymphopenia in sepsis. METHODS: This study employed the sepsis-related datasets (GSE65682 and GSE134347) and 9 PRMT genes. Firstly, we intersected the differentially expressed genes (DEGs) with weighted gene co-expression network analysis (WGCNA) module genes to identify DE-PRMT-related genes (DE-PRMT-RGs). Thereafter, candidate key genes were obtained after Mendelian randomization (MR) analysis and machine learning screening. Eventually, we subjected key genes identified by expression analysis and receiver operating characteristic (ROC) curves to gene set enrichment analysis (GSEA), immune infiltration analysis, immune checkpoint analysis, molecular docking, regulatory networks construction, and nomogram development. RESULTS: We firstly intersected 4,246 DEGs with 1,884 PRMT scoring module genes to obtain 969 DE-PRMT-RGs. Further MR analysis and machine learning jointly identified 5 candidate genes (CRLF3, ELAC2, PBX2, MCTP2, and EMB). Among these, ELAC2, PBX2, MCTP2, and EMB demonstrated consistent expression trends, with the area under the curve (AUC) values of the ROC curve exceeding 0.7 in GSE65682 and GSE134347. Therefore, they were defined as key PRMT-related genes. The GSEA analysis showed enrichment in cytoplasmic translation (ELAC2, MCTP2), non-coding RNA metabolism (EMB), and metabolic processes (PBX2). The immune infiltration analysis revealed a significant correlation between PBX2 and neutrophils, as well as between ELAC2/MCTP2/EMB with activated NK cells, CD8+ T cells. CONCLUSION: In this study, ELAC2, PBX2, MCTP2 and EMB were identified as key genes related to PRMT for sepsis, which provided a theoretical basis for the study of sepsis.